Introduction
============

Functional dyspepsia (FD) is a common functional gastrointestinal disorder with reported prevalence rates of between 11% and 29.2%.[@b1-jnm-23-504] Its symptoms are characterized by multifunctional disorders of the upper gastrointestinal (GI) tract mediated by altered GI motility,[@b2-jnm-23-504] abnormal acid secretion,[@b3-jnm-23-504] visceral hypersensitivity,[@b4-jnm-23-504] an imbalance of the autonomic nervous system,[@b5-jnm-23-504] psychological factors, and *Helicobacter pylori* infection.[@b6-jnm-23-504] The role of *H. pylori* infection in functional dyspepsia is not fully elucidated, and the therapeutic gains and symptomatic improvements following *H. pylori* eradication have been matters of debate.

In the literature, the main mechanisms of symptom development in *H. pylori*-associated functional dyspepsia reported were altered GI motility and mucosal inflammation.[@b6-jnm-23-504]--[@b12-jnm-23-504] Increasing eosinophils of the duodenum secondary to the exposure of gastric acid or food allergens to the duodenum might correlate with FD, and it has been suggested that there is a correlation between eosinophils and low-grade inflammation.[@b13-jnm-23-504],[@b14-jnm-23-504] Furthermore, it has been shown that the patients with microscopic duodenitis achieve greater symptomatic responses to *H. pylori* eradication than those without microscopic duodenitis.[@b15-jnm-23-504] In addition to a direct inflammatory response of the GI tract mucosa, decreased gastric acid secretions are common in patients with *H. pylori*-associated FD.[@b7-jnm-23-504],[@b8-jnm-23-504] This could be closely related to dysbiosis of gut microbiota. Recently, sequencing analysis of gut microbiota showed that *H. pylori* was not alone in the stomach and the interaction of *H. pylori* with those microorganisms might play a role in *H. pylori*-associated functional dyspepsia.[@b16-jnm-23-504],[@b17-jnm-23-504] In this study, we hypothesize that *H. pylori* infected patients diagnosed as FD might have dysbiosis of the gut microbiota. Most of them would also have irritable bowel syndrome (IBS).

Previous meta-analyses reported that eradication therapy produced marginal therapeutic gain and relief of symptoms in *H. pylori*-associated FD, although results differed depending on trial design and study selection criteria and quality.[@b10-jnm-23-504]--[@b12-jnm-23-504],[@b18-jnm-23-504]--[@b20-jnm-23-504] However, there has been no systemic review of the differences in efficacy according to the eradication regimen. We hypothesized that we would find different therapeutic effects for different eradication regimens. Broad spectrum antibiotics and longer treatment durations that had a sufficient effect on gut microbial imbalance would result in better symptomatic improvements after *H. pylori* eradication. The aim of this study was to evaluate whether the therapeutic gain would be different in patients with *H. pylori*-associated FD according to the type of antibiotic and duration of treatment. When FD studies excluding IBS cases were analyzed, we compared the therapeutic effects of *H. pylori* eradication on symptomatic improvement. We also compared the therapeutic effects in Asian and non-Asian populations, because there is considerable heterogeneity of symptoms and pathophysiology based on ethnic differences.

Materials and Methods
=====================

Search Strategy
---------------

The meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement.[@b21-jnm-23-504] The following procedure was used to collect clinical randomized controlled trials (RCTs) written in English undertaken up to August 2016 from the Pubmed, Embase, Cochrane library and CINAHL digital dissertation databases (undertaken by N.J.K., Medical Library, The Catholic University of Korea, Seoul, Korea). We used the following Medical Subject Heading (MeSH) terms and/or text words: *H. pylori* OR *Helicobacter pylori* OR HP AND dyspepsia OR functional dyspepsia OR non-ulcer dyspepsia OR FD AND eradication OR treatment OR cure. Two persons (Y.J.K. and W.C.C.) independently reviewed all potentially relevant material to determine whether or not it met the inclusion criteria.

Inclusion and Exclusion Criteria
--------------------------------

To be included in our meta-analysis studies had to meet following criteria; (1) RCTs with at least a 12-month follow-up period, (2) study population of patients with dyspepsia (symptom-based Rome I, II, or III classification), (3) symptoms of dyspepsia defined as an outcome measurement of the study, (4) *H. pylori* infection verified by rapid urease test, ^13^C breath test, or histologic examination, (5) treatment group received triple or quadruple therapy for 7--14 days, and (6) control group who only received placebo as intervention and were not treated with any other antibiotics or bismuth.

Studies were excluded if they were available only as an abstract, a review study, a case report, a study without raw data available for retrieval, a duplicate publication or if they were not written in English. When the patients of enrolled studies complained of reflux-like symptoms only, those studies were excluded.

Study Outcomes
--------------

The primary outcome of this study was the weighted summary odds ratio (OR) of symptomatic improvement in patients with and without *H. pylori* eradication with 95% CI. All of these analyses were planned a priori. Additional post hoc analyses were performed based the type of antibiotic, duration of therapy, and racial differences. The secondary outcomes were to analyze and compare the OR for each eradication antibiotic and duration of treatment (1 week vs longer than 10 days). Racial differences were compared by comparing Asian and non-Asian study populations. To evaluate the association of *H. pylori*-associated FD and IBS, we tried to find out whether IBS was included in methods of the articles. Since it was not clear if that IBS included the all studies, we reviewed the articles which mentioned IBS exclusion definitely studies using criteria of Rome II/III and explicit mentioned studies of IBS exclusion.

Study Selection and Data Extraction
-----------------------------------

Two investigators (Y.J.K. and W.C.C.) independently assessed the titles and abstracts of all retrieved papers and assessed their eligibility for inclusion in our meta-analysis. Full articles were scrutinized if the title and abstract were ambiguous. The reviewers used a standardized approach to conduct the literature search, data extraction, and quality assessment. The data sought included the study population, baseline characteristics of the participants, details related to the protocol, year of publication, therapy regimen of *H. pylori* eradications, definition of symptom relief and study outcome. When the results were combined and any disagreement occurred, this was resolved by the investigators.

Statistical Methods
-------------------

The R language meta-package version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria) was used for the meta-analysis. The summary OR with 95% CI was evaluated for quantitative analyses. Heterogeneity among the studies was measured using Higgin's I^2^ statistics and 95% CIs were calculated. When there was substantial heterogeneity (I^2^ \> 50%), all analyses were based on the random-effect model (DerSimonian-Laird method); otherwise (I^2^ \< 50%), the fixed effect model (inverse variance method) was used. To test for publication bias, we used a test for asymmetry of the funnel plot. A *P*-value of less than 0.05 was considered statistically significant. Meta-analysis of variance (ANOVA) was used for subgroup analysis based on type of antibiotic and duration of treatment regimen. All the statistical methods of this study were performed by S.H.K. and J.H.Y. from Bio-Age, Medical Development Institute, Seoul, Korea.

Results
=======

Study Characteristics
---------------------

The initial search strategy identified 1130 articles. After removal of duplicates, the 727 remaining articles were screened. After reviewing the title and abstracts, 6 trials were available only as abstracts and 650 trials were irrelevant, leaving 71 potentially relevant studies. In the remaining articles, 1 study was excluded because the manuscript was not written in English, 3 trials did not use dichotomous outcomes, and 41 trials did not meet the eligibility criteria. Reviewing the full manuscripts, we identified 16 RCTs with a total of 1920 subjects that met the inclusion criteria ([Table 1](#t1-jnm-23-504){ref-type="table"} and [Fig. 1](#f1-jnm-23-504){ref-type="fig"}).[@b22-jnm-23-504]--[@b37-jnm-23-504]

Study Result
------------

The cumulative eradication rate of *H. pylori* in the treatment group was 80.3% ([Table 1](#t1-jnm-23-504){ref-type="table"}). In the meta-analysis of all 16 RCTs, 13 trials reported successful symptom relief results. [Figure 2](#f2-jnm-23-504){ref-type="fig"} shows the existence of publication bias according to the test for the asymmetry of the funnel plot (*P* = 0.338). Because there was no significant heterogeneity (Higgins' I^2^ = 27.0%), we summarized OR using a fixed effect model. The summary OR was 1.33 (95% CI, 1.16--1.54; *P* \< 0.01), indicating that the patients with *H. pylori*-associated FD had a greater than 1.33-fold increased probability of symptom relief after eradication. ([Table 2](#t2-jnm-23-504){ref-type="table"} and [Fig. 3](#f3-jnm-23-504){ref-type="fig"})

We analyzed symptom improvement according to the antibiotic type. The meta-ANOVA analysis showed more significant improvements with metronidazole (OR, 1.87; 95% CI, 1.26--2.77; *P* \< 0.01) compared to clarithromycin (OR, 1.29; 95% CI, 1.11--1.50; *P* \< 0.01) in the eradication group. Tinidazole was included in the metronidazole group as antibiotics of the same drug class, nitroimidazole antimicrobial. The metronidazole-based regimen produced more therapeutic gain than the clarithromycin-based regimen in *H. pylori*-associated FD ([Table 3](#t3-jnm-23-504){ref-type="table"} and [4](#t4-jnm-23-504){ref-type="table"} and [Fig. 4](#f4-jnm-23-504){ref-type="fig"}).

The selected studies used different treatment regimen durations (7, 10, or 14 day regimen). We divided the trials into 2 subgroups according to the duration of treatment regimen. Eight trials used a 7-day regimen and the remaining 8 trials administered a regimen of 10 days or more. Subgroup analysis confirmed that a regimen of 10 days or more yielded superior relief of symptoms (OR, 1.45; 95% CI, 1.09--1.93; *P* = 0.011). There was a significant difference between the 2 groups ([Table 5](#t5-jnm-23-504){ref-type="table"} and [Fig. 5](#f5-jnm-23-504){ref-type="fig"}).

When exclusive diagnostic criteria for FD (excluding IBS) were adopted in the study enrollment, 8 studies were sub-analyzed - studies using criteria of Rome II/III[@b24-jnm-23-504],[@b30-jnm-23-504],[@b31-jnm-23-504],[@b34-jnm-23-504] and explicit mentioned studies of IBS exclusion.[@b22-jnm-23-504],[@b25-jnm-23-504],[@b27-jnm-23-504],[@b28-jnm-23-504] The summary OR was statistically insignificant (OR, 1.12; 95% CI, 0.99--1.26; *P* = 0.263) ([Fig. 6](#f6-jnm-23-504){ref-type="fig"}). Thirteen studies that were performed on non-Asian populations showed statistically significant benefits for dyspeptic symptom relief, whereas the 3 trials performed on Asian populations revealed insignificant results ([Table 6](#t6-jnm-23-504){ref-type="table"} and [Fig. 7](#f7-jnm-23-504){ref-type="fig"}).

Discussion
==========

It is still unclear whether *H. pylori* infection causes dyspeptic symptoms. Our meta-analysis is a comprehensive study focusing on a comparison of efficacy based on antibiotic type used and the duration of the eradication regimen on symptomatic improvements after *H. pylori* eradication. The strength of this meta-analysis was that it includes more recent trials and subgroup analysis according to *H. pylori* eradication regimens. Multiple complex factors are thought to be involved in the pathophysiology of FD such as gastro-duodenal inflammation by intestinal microbiota; our results support such a theory.

Several studies on *H. pylori*-associated FD have focused on changes in the intestinal environment.[@b15-jnm-23-504]--[@b17-jnm-23-504],[@b38-jnm-23-504] Intestinal microbiota play an important role in the maintenance of host health by providing energy, nutrients, and immunological protection and its imbalance can provoke various GI symptoms and disease.[@b39-jnm-23-504] Because *H. pylori*-associated FD and intestinal dysbiosis could be shared with common pathogenesis such as impaired motility, there is a close relationship.[@b14-jnm-23-504] Another possible pathogenesis is based on the decreased secretion of gastric acid by long-term infection of *H. pylori*. In patients with severe atrophy induced by *H. pylori* infection, acid secretion would be compromised and subsequently it results in bacterial overgrowth in the intestine. Previously, it has been demonstrated that patients who complained of dyspeptic symptoms would have an increased risk of intestinal dysbiosis.[@b14-jnm-23-504],[@b38-jnm-23-504],[@b40-jnm-23-504] Further prospective evaluations are necessary to investigate whether patients with severe atrophic change would benefit on symptomatic improvement from *H. pylori* eradication.

Altered gut microbiota have been considered as a main pathophysiology of IBS and manipulation of gut microbiota represents a new strategy for the treatment of IBS. In the overlap syndrome consisting of FD and IBS, intestinal dysbiosis might be a common etiology and dominant pathogenesis. Recent clinical data revealed that intestinal dysbiosis was diagnosed in FD patients with refractory symptoms.[@b38-jnm-23-504] Another study on *H. pylori*-negative Asian FD patients without IBS-overlap showed that 2-week therapy with rifaximin was efficient in a randomized placebo-controlled trial.[@b41-jnm-23-504] This evidence suggested that low-level inflammation of the intestine caused by imbalance of intestinal microbiome might be one of mechanisms of functional dyspepsia. In the near future, new classification of functional GI disorder should be categorized according to the state of small intestinal microbiome. In addition, the concept of "colo-gastric reflex" is another pathophysiology of IBS. In recent human data, gastric accommodation regularly affects lower GI tract function and colonic gaseous distension or constipation decrease gastric accommodation or gastric emptying. It was called as the "colo-gastric reflex."[@b42-jnm-23-504] In other words, the relationship between dyspepsia and the colonic distension could be even more important.

We hypothesized that many patients with *H. pylori*-associated FD might have FD-IBS overlap and this concept was first applied. When all patients with IBS criteria were excluded, there was no statistical significance of symptomatic improvement after *H. pylori* eradication. However, it was insufficient to make a concrete conclusion because the different types of Rome criteria applied to the different studies and the diagnostic criteria of FD and IBS were mutually exclusive. It was not until recently that overlap syndrome was paid attention. In this point of view, *H. pylori*-associated FD could be a new disease category. Previous reports revealed that responders at 3 months and *H. pylori* eradicated status were associated with improvement of dyspeptic symptoms at 1 year, regardless of the overplayed IBS.[@b43-jnm-23-504] Gastric mucosal inflammation induced by *H. pylori* infection was a crucial role in symptom generation, and the control of inflammation resulted in symptom improvement. Therefore, the Kyoto Global Consensus report insisted that *H. pylori*-associated dyspepsia was not as a FD, but a kind of infectious disease.[@b44-jnm-23-504]

Several antibiotics with various spectra of activity have been used for *H. pylori* eradication therapy. Clarithromycin is a representative of the macrolide antibiotics and these provide coverage of gram-positive bacteria, whereas metronidazole is the drug of choice for the treatment of anaerobic infection and the representative treatment drug for intestinal dysbiosis.[@b45-jnm-23-504] Metronidazole-combined with these antibiotics are thought to be combinations that can cover broader antibacterial spectrum including anaerobes. Our results revealed that metronidazole-containing regimens were significantly more effective for symptom relief compared to clarithromycin-containing regimens. This was because the use of metronidazole in the treatment of *H. pylori* eradication brought about the secondary therapeutic effect of modifying the gut microbiota.

In FD, mucosal inflammation could play an important role and it was demonstrated that increased mast cells or eosinophils in the gastroduodenal mucosa were associated with symptom generation.[@b46-jnm-23-504],[@b47-jnm-23-504] However, it was questionable whether inflammatory cells were eliminated or lymphoid follicles healed completely after *H. pylori* eradication. Moreover, the influence of antibiotics on the intestinal flora could be temporary, and it would return to previous state after antibiotic therapy.[@b48-jnm-23-504] Previously, several researchers insisted that at least 6 to 12 months of observation period should be required to judge the outcome of dyspeptic symptoms after successful eradication. Gastric mucosal inflammation activity and physiologic functions including acid secretion could recover or stabilize after 6 months.[@b44-jnm-23-504] The restoration of gastric physiologic functions would have a possibility to modify intestinal dysbiosis.

In 13 studies performed on a non-Asian population, there were statistically significant benefits for dyspeptic symptom relief, whereas the 3 trials performed on Asian populations revealed insignificant results. These differences in race-to-race efficacy are contrary to the predicted results. In Asia, *H. pylori* infection is common at a younger age, and it is more likely that atrophic gastritis has progressed over a longer period of time. In general, more advanced hypo-secretory stomach due to long-term *H. pylori* infection and atrophy of the gastric mucosa is known as a risk factor of dysbiosis. Therefore, Asian *H. pylori*-infected patients are more likely to have a more advanced hypo-secretory stomach. As a result, dysbiosis is more likely to be more prominent in Asian *H. pylori*-infected patients, and the potential for efficacy with antibiotic treatment may increase. However, in the all trials on Asian populations, the 7-day regimen was adopted, and there was a possibility of insufficient dose of antibiotic treatment. In addition, small sample size and a wide confidence interval limits the interpretation of the results. Brain-gut interaction was one of the important mechanisms of functional dyspepsia and it was unlikely that the Rome criteria completely reflect the various symptoms, especially in Asian patients with FD. Large-scale prospective studies should be needed in Asia, particularly in China and Korea which are well known areas of high prevalence of *H. pylori*.

There were potential limitations in this study. First, our literature search was restricted to English-language reports because of translation limitations, which could have introduced some bias. The relatively small number of studies on Asian populations is thought to have resulted in reduced reliability. Second, this study was not a direct pharmaceutical comparison, but a relative comparison via OR. However, based on Monson's experience, an OR of 1.87 is highly effective for symptomatic improvement[@b49-jnm-23-504]; therefore, we do not think our comparison of the results was insufficient for our research purpose. Third, differences in enrollment criteria may have created heterogeneous *H. pylori*-associated FD populations in several clinical trials.

In conclusion, *H. pylori* eradication for FD could be an effective treatment strategy. When clinicians choose an eradication regimen for *H. pylori*-associated FD, administering metronidazole for 10 days or more would provide a great benefit for symptom improvement. In the future, more prospective RCTs are necessary for direct comparison of metronidazole and other antibiotic regimens for treating this disorder.
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###### 

The Baseline Characteristics of the Enrolled Studies

  Studies                                              Country       HP eradication rate   Age    Sex           Smoking       Drinking                                   
  ---------------------------------------------------- ------------- --------------------- ------ ------------- ------------- ---------- ------- ------- ------- ------- -------
  Ang et al,[@b22-jnm-23-504] 2006                     Singapore     73.2%                 0%     38.6          38.4          35.2%      37.3%                           
  Blum et al,[@b23-jnm-23-504] 1998                    Multicenter   79%                   2%     47            47            39.6%      43.3%   18.3%   16.5%   28.0%   25.6%
  Froehlich et al,[@b25-jnm-23-504] 2001               Switzerland   75%                   4%     43.6 ± 12.4   45.6 ± 14.2   49%        40%                             
  Gisbert et al,[@b26-jnm-23-504] 2004                 Spain         76%                          42            41            30%        28%     33%     36%             
  Gwee et al,[@b27-jnm-23-504] 2009                    Singapore     68.3%                 4.9%   44.7 ± 11.4   36.1 ± 12.1   43.9%      46.3%   30.7%   26.7%   17.9%   27.8%
  Hsu et al,[@b28-jnm-23-504] 2001                     China         78%                   0%     50.3 ± 15.1   51.6 ± 16.4   49.4%      47.6%   15.7%   14.6%   7.2%    4.9%
  Koskenpato et al,[@b29-jnm-23-504] 2001              Finland       82%                   1%     51.5 ± 9.5    51.8 ± 11.8   30%        39%     54%     59%             
  Mazzoleni et al,[@b31-jnm-23-504] 2011               Brazil        88.6%                 7.4%   46.1 ± 12.4   46.0 ± 12.2   23.4%      19.2%   45.3%   39.4%   15.4%   14.3%
  Mazzoleni et al,[@b30-jnm-23-504] 2006               Brazil        91.3%                 0%     43.2 ± 11.9   39.2 ± 13.8   19.6%      25.6%   17.4%   11.6%   13.0%   16.3%
  McColl et al,[@b32-jnm-23-504] 1998                  UK            88%                   5%     42 ± 12       42.2 ± 13     51%        47%     34%     33%             
  Sodhi et al,[@b33-jnm-23-504] 2013                   India         66.6%                 6.6%   46            43            29.3%      35.7%   33%     20%             
  Talley et al,[@b34-jnm-23-504] 1999                  Australia     85%                   4%     51 ± 14       49 ± 13       38%        33%     20%     27.5%   38%     36%
  Talley et al,[@b35-jnm-23-504] 1999                  Australia     90%                   2%     46.3          46.5          43%        48%     27%     26%     41%     41%
  Veldhuyzen van Zanten et al,[@b36-jnm-23-504] 2003   Canada        82%                   6%     47 ± 13       49 ± 13       41.3%      50.0%   34.7%   26.8%   20.6%   23.2%
  Bruley Des Varannes et al,[@b24-jnm-23-504] 2001     France        69%                   18%    50 ± 16       52 ± 14       43%        46%     26%     27%     28%     30%
  Yazdanbod et al,[@b37-jnm-23-504] 2015               Iran          80.3%                 4.9%                                                                          

HP, *Helicobacter pylori*.

###### 

The Results of Meta-analysis for the Effects of *Helicobacter pylori* Eradication on Functional Dyspepsia

  Studies                                              Treatment   Control   OR      95% lower CI   95% upper CI   Weights   *P*-value                            
  ---------------------------------------------------- ----------- --------- ------- -------------- -------------- --------- ----------- ------- -------- ------- ---------
  Ang et al,[@b22-jnm-23-504] 2006                     45          71        0.634   40             59             0.678     0.822       0.397   1.704    3.8     
  Blum et al,[@b23-jnm-23-504] 1998                    45          164       0.274   34             164            0.207     1.446       0.868   2.408    7.8     
  Froehlich et al,[@b25-jnm-23-504] 2001               15          92        0.163   13             88             0.148     1.124       0.501   2.521    3.1     
  Gisbert et al,[@b26-jnm-23-504] 2004                 21          34        0.618   8              16             0.500     1.615       0.487   5.361    1.4     
  Gwee et al,[@b27-jnm-23-504] 2009                    10          41        0.244   3              41             0.073     4.086       1.034   16.155   1.1     
  Hsu et al,[@b28-jnm-23-504] 2001                     47          81        0.580   44             80             0.550     1.131       0.606   2.110    5.2     
  Koskenpato et al,[@b29-jnm-23-504] 2001              16          77        0.208   11             74             0.149     1.502       0.646   3.496    2.8     
  Mazzoleni et al,[@b31-jnm-23-504] 2011               94          201       0.468   72             203            0.355     1.598       1.072   2.383    12.7    
  Mazzoleni et al,[@b30-jnm-23-504] 2006               16          46        0.348   9              45             0.200     2.133       0.825   5.514    2.2     
  McColl et al,[@b32-jnm-23-504] 1998                  33          160       0.206   11             158            0.070     3.472       1.686   7.152    3.9     
  Sodhi et al,[@b33-jnm-23-504] 2013                   95          259       0.367   72             260            0.277     1.513       1.044   2.192    14.7    
  Talley et al,[@b34-jnm-23-504] 1999                  32          133       0.241   31             142            0.218     1.135       0.646   1.991    6.4     
  Talley et al,[@b35-jnm-23-504] 1999                  69          170       0.406   71             167            0.425     0.924       0.599   1.425    10.7    
  Veldhuyzen van Zanten et al,[@b36-jnm-23-504] 2003   44          75        0.587   46             82             0.561     1.111       0.590   2.093    5.0     
  Bruley Des Varannes et al,[@b24-jnm-23-504] 2001     55          129       0.426   38             124            0.306     1.682       1.003   2.821    7.5     
  Yazdanbod et al,[@b37-jnm-23-504] 2015               87          186       0.468   83             173            0.480     0.953       0.630   1.443    11.7    
  Total (Fixed effect model)                                                                                                 1.334       1.157   1.537    100.0   \< 0.01

*P*-value of test of heterogeneity among studies = 0.152; Higgins' I^2^ = 27.0% (0.0%, 60.0%).

###### 

Meta-analysis on Symptomatic Improvement Following *Helicobacter pylori* Eradication by the Regimen Including Nitroimidazole Antimicrobial (Metronidazole and Tinidazole)

  Studies                                   Treatment   Control   OR      95% lower CI   95% upper CI   Weights   *P*-value                            
  ----------------------------------------- ----------- --------- ------- -------------- -------------- --------- ----------- ------- -------- ------- ---------
  Gwee et al,[@b27-jnm-23-504] 2009         10          41        0.244   3              41             0.073     4.086       1.034   16.155   8.2     
  Hsu et al,[@b28-jnm-23-504] 2001          47          81        0.580   44             80             0.550     1.131       0.606   2.110    40.1    
  Koskenpato et al,[@b29-jnm-23-504] 2001   16          77        0.208   11             74             0.149     1.502       0.646   3.496    21.8    
  McColl et al,[@b32-jnm-23-504] 1998       33          160       0.206   11             158            0.070     3.472       1.686   7.152    29.8    
  Total (Fixed effect model)                                                                                      1.870       1.260   2.774    100.0   \< 0.01

*P*-value of test of heterogeneity among studies = 0.223; Higgins' I^2^ = 56.0% (0.0%, 85.4%).

###### 

Meta-analysis on Symptomatic Improvement Following *Helicobacter pylori* Eradication by the Regimen Including Clarithromycin

  Studies                                              Treatment   Control   OR      95% lower CI   95% upper CI   Weights   *P*-value                            
  ---------------------------------------------------- ----------- --------- ------- -------------- -------------- --------- ----------- ------- -------- ------- -------
  Ang et al,[@b22-jnm-23-504] 2006                     45          71        0.634   40             59             0.678     0.822       0.397   1.704    4.3     
  Blum et al,[@b23-jnm-23-504] 1998                    45          164       0.274   34             164            0.207     1.446       0.868   2.408    8.8     
  Froehlich et al,[@b25-jnm-23-504] 2001               15          92        0.163   13             88             0.148     1.124       0.501   2.521    3.5     
  Gisbert et al,[@b26-jnm-23-504] 2004                 21          34        0.618   8              16             0.500     1.615       0.487   5.361    1.6     
  Gwee et al,[@b27-jnm-23-504] 2009                    10          41        0.244   3              41             0.073     4.086       1.034   16.155   1.2     
  Mazzoleni et al,[@b31-jnm-23-504] 2011               94          201       0.468   72             203            0.355     1.598       1.072   2.383    14.4    
  Mazzoleni et al,[@b30-jnm-23-504] 2006               16          46        0.348   9              45             0.200     2.133       0.825   5.514    2.5     
  Sodhi et al,[@b33-jnm-23-504] 2013                   95          259       0.367   72             260            0.277     1.513       1.044   2.192    16.6    
  Talley et al,[@b34-jnm-23-504] 1999                  32          133       0.241   31             142            0.218     1.135       0.646   1.991    7.2     
  Talley et al,[@b35-jnm-23-504] 1999                  69          170       0.406   71             167            0.425     0.924       0.599   1.425    12.2    
  Veldhuyzen van Zanten et al,[@b36-jnm-23-504] 2003   44          75        0.587   46             82             0.561     1.111       0.590   2.093    5.7     
  Bruley Des Varannes et al,[@b24-jnm-23-504] 2001     55          129       0.426   38             124            0.306     1.682       1.003   2.821    8.6     
  Yazdanbod et al,[@b37-jnm-23-504] 2015               87          186       0.468   83             173            0.480     0.953       0.630   1.443    13.3    
  Total (Fixed effect model)                                                                                                 1.286       1.106   1.497    100.0   0.001

*P*-value of test of heterogeneity among studies = 0.351; Higgins' I^2^ = 9.5% \[0.0%, 47.9%\]

###### 

Meta-analysis on Symptomatic Improvement Following *Helicobacter pylori* Eradication According to Duration

###### 

\(A\) 7-day regimen

  Studies                                              Treatment   Control   OR      95% lower CI   95% upper CI   Weights   *P*-value                            
  ---------------------------------------------------- ----------- --------- ------- -------------- -------------- --------- ----------- ------- -------- ------- -------
  Ang et al,[@b22-jnm-23-504] 2006                     45          71        0.634   40             59             0.678     0.822       0.397   1.704    9.5     
  Blum et al,[@b23-jnm-23-504] 1998                    45          164       0.274   34             164            0.207     1.446       0.868   2.408    19.5    
  Froehlich et al,[@b25-jnm-23-504] 2001               15          92        0.163   13             88             0.148     1.124       0.501   2.521    7.8     
  Gwee et al,[@b27-jnm-23-504] 2009                    10          41        0.244   3              41             0.073     4.086       1.034   16.155   2.7     
  Hsu et al,[@b28-jnm-23-504] 2001                     47          81        0.580   44             80             0.550     1.131       0.606   2.110    13.0    
  Talley et al,[@b34-jnm-23-504] 1999                  32          133       0.241   31             142            0.218     1.135       0.646   1.991    16.0    
  Veldhuyzen van Zanten et al,[@b36-jnm-23-504] 2003   44          75        0.587   46             82             0.561     1.111       0.590   2.093    12.6    
  Bruley Des Varannes et al,[@b24-jnm-23-504] 2001     55          129       0.426   38             124            0.306     1.682       1.003   2.821    18.9    
  Total (Fixed effect model)                                                                                                 1.281       1.023   1.605    100.0   0.031

*P*-value of test of heterogeneity among studies = 0.532; Higgins' I^2^ = 0.0% (0.0%, 62.6%).

###### 

\(B\) 10-day or more regimen

  Studies                                   Treatment   Control   OR      95% lower CI   95% upper CI   Weights   *P*-value                           
  ----------------------------------------- ----------- --------- ------- -------------- -------------- --------- ----------- ------- ------- ------- -------
  Gisbert et al,[@b26-jnm-23-504] 2004      21          34        0.618   8              16             0.500     1.615       0.487   5.361   4.7     
  Koskenpato et al,[@b29-jnm-23-504] 2001   16          77        0.208   11             74             0.149     1.502       0.646   3.496   8.1     
  Mazzoleni et al,[@b31-jnm-23-504] 2011    94          201       0.468   72             203            0.355     1.598       1.072   2.383   17.8    
  Mazzoleni et al,[@b30-jnm-23-504] 2006    16          46        0.348   9              45             0.200     2.133       0.825   5.514   6.8     
  McColl et al,[@b32-jnm-23-504] 1998       33          160       0.206   11             158            0.070     3.472       1.686   7.152   9.9     
  Sodhi et al,[@b33-jnm-23-504] 2013        95          259       0.367   72             260            0.277     1.513       1.044   2.192   18.7    
  Talley et al,[@b35-jnm-23-504] 1999       69          170       0.406   71             167            0.425     0.924       0.599   1.425   16.8    
  Yazdanbod et al,[@b37-jnm-23-504] 2015    87          186       0.468   83             173            0.480     0.953       0.630   1.443   17.3    
  Total (random effect model)                                                                                     1.447       1.088   1.925   100.0   0.011

*P*-value of test of heterogeneity among studies = 0.046; Higgins' I^2^ = 51.0% (0.0%, 78.1%).

###### 

Meta-analysis on Symptomatic Improvement Following *Helicobacter pylori* Eradication by Ethnic Difference

###### 

\(A\) Asian

  Studies                             Treatment   Control   OR      95% lower CI   95% upper CI   Weights   *P*-value                            
  ----------------------------------- ----------- --------- ------- -------------- -------------- --------- ----------- ------- -------- ------- -------
  Ang et al,[@b22-jnm-23-504] 2006    45          71        0.634   40             59             0.678     0.822       0.397   1.704    37.8    
  Gwee et al,[@b27-jnm-23-504] 2009   10          41        0.244   3              41             0.073     4.086       1.034   16.155   10.6    
  Hsu et al,[@b28-jnm-23-504] 2001    47          81        0.580   44             80             0.550     1.131       0.606   2.110    51.6    
  Total (Fixed effect model)                                                                                1.149       0.734   1.799    100.0   0.542

*P*-value of test of heterogeneity among studies = 0.152; Higgins' I^2^ = 27.0% (0.0%, 60.0%).

###### 

\(B\) Non-Asian

  Studies                                              Treatment   Control   OR      95% lower CI   95% upper CI   Weights   *P*-value                           
  ---------------------------------------------------- ----------- --------- ------- -------------- -------------- --------- ----------- ------- ------- ------- ----------
  Blum et al,[@b23-jnm-23-504] 1998                    45          164       0.274   34             164            0.207     1.446       0.868   2.408   8.6     
  Froehlich et al,[@b25-jnm-23-504] 2001               15          92        0.163   13             88             0.148     1.124       0.501   2.521   3.4     
  Gisbert et al,[@b26-jnm-23-504] 2004                 21          34        0.618   8              16             0.500     1.615       0.487   5.361   1.6     
  Koskenpato et al,[@b29-jnm-23-504] 2001              16          77        0.208   11             74             0.149     1.502       0.646   3.496   3.1     
  Mazzoleni et al,[@b31-jnm-23-504] 2011               94          201       0.468   72             203            0.355     1.598       1.072   2.383   14.1    
  Mazzoleni et al,[@b30-jnm-23-504] 2006               16          46        0.348   9              45             0.200     2.133       0.825   5.514   2.5     
  McColl et al,[@b32-jnm-23-504] 1998                  33          160       0.206   11             158            0.070     3.472       1.686   7.152   4.3     
  Sodhi et al,[@b33-jnm-23-504] 2013                   95          259       0.367   72             260            0.277     1.513       1.044   2.192   16.3    
  Talley et al,[@b34-jnm-23-504] 1999                  32          133       0.241   31             142            0.218     1.135       0.646   1.991   7.1     
  Talley et al,[@b35-jnm-23-504] 1999                  69          170       0.406   71             167            0.425     0.924       0.599   1.425   11.9    
  Veldhuyzen van Zanten et al,[@b36-jnm-23-504] 2003   44          75        0.587   46             82             0.561     1.111       0.590   2.093   5.6     
  Bruley Des Varannes et al,[@b24-jnm-23-504] 2001     55          129       0.426   38             124            0.306     1.682       1.003   2.821   8.4     
  Yazdanbod et al,[@b37-jnm-23-504] 2015               87          186       0.468   83             173            0.480     0.953       0.630   1.443   13.1    
  Total (fixed effect model)                                                                                                 1.356       1.167   1.575   100.0   \< 0.001

*P*-value of test of heterogeneity among studies = 0.191; Higgins' I^2^ = 25.0% (0.0 %, 61.0%).
